EDAP TMS S.A. to Present at the Roth Capital 2007 Orange County Conference
EDAP TMS S.A. to Present at the Roth Capital 2007 Orange County Conference
EDAP will offer an audio and slide webcast of the conference presentation online at www.edap-tms.com under Investor Relations.
Institutional investors interested in meeting with management should contact Roth Capital Partners or Halliburton Investor Relations (Matt Kreps, 972-458-8000). Management will also host meetings in San Francisco and Minneapolis during the week. Information regarding the conference can be found online at www.rothconference.com. The conference is available by invitation of Roth Capital Partners only.
EDAP TMS S.A. provides the Ablatherm-HIFU medical device for the treatment of localized prostate cancer by High Intensity Focused Ultrasound. Ablatherm-HIFU is widely regarded as the most advanced and clinically proven HIFU device for prostate cancer. HIFU therapy is fully approved in Europe, Canada, Australia and other regions as a noninvasive therapeutic choice offering patients a high rate of success with low side effects. The treatment is also proven effective with low side effects for patients suffering a recurrence of localized prostate cancer after prior radiation therapy.
Ablatherm-HIFU therapy is reimbursed in certain markets and the company continues to seek additional reimbursements. EDAP is presently increasing its marketing activity in conjunction with its approval for use in key European markets and a growing clinical interest from the urology community based on published and peer reviewed studies supporting Ablatherm-HIFU as an effective and attractive therapeutic choice for nonsurgical patients.
Information about EDAP and HIFU therapy can be found online at www.edap-tms.com and www.hifu-planet.com .
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Halliburton Investor Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com.